Tag Archives: lucentis

November, 2018

12 November
Ophthotech Announces Results from Phase 2a Safety Trial of Zimura in Combination with Lucentis in Wet Age-Related Macular Degeneration

NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation (NASDAQ:OPHT) today announced the results from its Phase 2a safety trial of Zimura® (avacincaptad pegol), the Company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD). This trial was designed to evaluate the safety of different dosage regimens of Zimura combination therapy in wet AMD …
Share

12 December
Ophthotech’s Anti-PDGF Therapy Fails Phase 3 Trials for Treatment of Wet AMD

NEW YORK–(BUSINESS WIRE)– Ophthotech Corporation (Nasdaq:OPHT) today announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal Phase 3 clinical trials investigating the superiority of Fovista® (pegpleranib) anti-PDGF therapy in combination with Lucentis® (ranibizumab) anti-VEGF therapy compared to Lucentis® monotherapy …
Share

17 October
FDA Approves Genentech’s Lucentis Prefilled Syringe

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis® (ranibizumab injection) 0.5 mg prefilled syringe (PFS) as a new method of administering the medicine. Like the Lucentis 0.5 mg vial, …
Share

8 August
Pfenex Regains Full Rights to its Biosimilar Candidate and Announces Phase I/II Results

SAN DIEGO, Aug. 8, 2016 /PRNewswire/ — Pfenex Inc. (NYSE MKT: PFNX) announced today that the company will regain the full rights to PF582, a biosimilar candidate to Lucentis®, following our partner’s strategic review of the current therapeutic focus of its biosimilar pipeline. “With Pfenex regaining the rights to PF582 …
Share

9 February
FDA Approves Genentech’s Lucentis for Treatment of Diabetic Retinopathy

Genentech’s Lucentis (ranibizumab injection) received expanded US approval for treatment of diabetic retinopathy (DR) in patients with diabetic macular edema (DME). The company announced that the drug received its fourth indication approved by the US Food and Drug Administration (FDA). The agency approved Lucentis 0.3 mg to be used along …
Share